Ming-yu Lai - Publications

Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data.

Journal: Journal of hematology & oncology

Published: April 26, 2026

Vitamin B5 supports anti-PD1 response in HER2-positive gastric cancer and enhances interaction between naïve B cells and T cells.

Journal: Nature communications

Published: September 22, 2025

Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.

Journal: Cancer immunology, immunotherapy : CII

Published: March 18, 2024

The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis.

Journal: Cancer immunology, immunotherapy : CII

Published: February 26, 2024

The relationship between brain metastasis and HER2 expression status in gastric cancer.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: June 26, 2023

Whole-Exome Sequencing Among Chinese Patients With Hereditary Diffuse Gastric Cancer.

Journal: JAMA network open

Published: December 09, 2022

Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins.

Journal: Cell reports

Published: September 22, 2022

Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis.

Journal: International immunopharmacology

Published: January 04, 2022